Search - tctmd.com

Displaying 1 - 20 of 739

Sort: Relevancy | Date

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Conference News TCT 2016

TRANSFORM-OCT: 生物可吸收和耐久聚合物 DES 早期和晚期愈合率类似

Michael O'Riordan

November 02, 2016

News Conference News TCT 2016

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

Michael O'Riordan

November 02, 2016

News Conference News TCT 2016

TRANSFORM-OCT: Similar Curación Precoz y Tardía con SLF Bioreabsorbibles y de Polímero Duradero

Michael O'Riordan

November 02, 2016

Presentation TCT 2016

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Vivek Y. Reddy

November 01, 2016

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

Presentation TCT 2016

Case Conclusion: How Did We Treat Our Patient?

Presenter: George D. Dangas, Fabio Felice Tarantino, Massimo Fineschi

November 01, 2016

Presentation TCT 2016

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Presenter: Martin W. Bergmann, Samir R. Kapadia, Jason H. Rogers

November 01, 2016

Presentation TCT 2016

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Presenter: Martin W. Bergmann, Samir R. Kapadia, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Case Introduction: What Device(s) to Choose in a Patient With NSTE-ACS?

Presenter: George D. Dangas, Fabio Felice Tarantino, Massimo Fineschi

November 01, 2016

Presentation TCT 2016

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Presenter: Martin W. Bergmann, Samir R. Kapadia, Ashish Pershad

November 01, 2016

Presentation TCT 2016

Case Conclusion: How Did We Treat Our Patient?

Presenter: Roxana Mehran, Ferdinando Varbella, Alberto Menozzi

November 01, 2016

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

To Pretreat or Not to Pretreat? The DUBIUS Trial

Presenter: Roxana Mehran, Ferdinando Varbella, Giuseppe Tarantini

November 01, 2016

Presentation TCT 2016

Case Introduction: An Elderly Patient With NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Alberto Menozzi

November 01, 2016

Presentation TCT 2016

Case Presentation: ACS Intervention in the Emerging BRS Era

Presenter: Bagrat Alekyan, Grzegorz L. Kaluza, Evgeny V. Merkulov

November 01, 2016

Presentation TCT 2016

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Roxana Mehran

November 01, 2016

Presentation TCT 2016

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx

November 01, 2016

Presentation TCT 2016

Very Long Term Outcomes after FFR-Based Decision-Making

Presenter: Nick Curzen, Nils Johnson, Frederik M. Zimmermann

November 01, 2016

Advertisement

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

TRANSFORM-OCT: 生物可吸收和耐久聚合物 DES 早期和晚期愈合率类似

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

TRANSFORM-OCT: Similar Curación Precoz y Tardía con SLF Bioreabsorbibles y de Polímero Duradero

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Case Conclusion: How Did We Treat Our Patient?

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Case Introduction: What Device(s) to Choose in a Patient With NSTE-ACS?

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Case Conclusion: How Did We Treat Our Patient?

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

To Pretreat or Not to Pretreat? The DUBIUS Trial

Case Introduction: An Elderly Patient With NSTE-ACS

Case Presentation: ACS Intervention in the Emerging BRS Era

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Very Long Term Outcomes after FFR-Based Decision-Making

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content